The following ventures have been selected by the
INCATE Selection Committee
Tackling resistant infections with virulence inhibition.
Invitris developed the worldwide first platform technology to synthesize arbitrary phages within a single system, thus enabling full scalability of therapeutic phage isolation, modification, production, and application.
Myxobiotics is a start-up company discovering and developing novel antibiotics from natural products first isolated and characterized from myxobacteria.
At smartbax we develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
The following ventures were selected
at INCATE pitch events
LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation vaccines for the prevention of life-threatening diseases.
Stay informed on events and applications
© 2021 INCATE • Privacy Options • Imprint • Terms and Conditions